The stock of Esperion Therapeutics Inc (ESPR) has gone up by 12.99% for the week, with a -4.40% drop in the past month and a -19.44% drop in the past quarter. The volatility ratio for the week is 6.83%, and the volatility levels for the past 30 days are 7.40% for ESPR. The simple moving average for the past 20 days is 7.04% for ESPR’s stock, with a -18.02% simple moving average for the past 200 days.
Is It Worth Investing in Esperion Therapeutics Inc (NASDAQ: ESPR) Right Now?
Company’s 36-month beta value is 0.79.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for ESPR is 194.37M, and currently, short sellers hold a 14.99% ratio of that floaft. The average trading volume of ESPR on March 25, 2025 was 4.19M shares.
ESPR) stock’s latest price update
Esperion Therapeutics Inc (NASDAQ: ESPR) has experienced a rise in its stock price by 2.96 compared to its previous closing price of 1.69. However, the company has seen a gain of 12.99% in its stock price over the last five trading days. zacks.com reported 2025-03-21 that Esperion plans to begin two phase III studies on bempedoic acid alone and in combination with ezetimibe in pediatric patients with familial hypercholesterolemia.
Analysts’ Opinion of ESPR
Many brokerage firms have already submitted their reports for ESPR stocks, with Goldman repeating the rating for ESPR by listing it as a “Neutral.” The predicted price for ESPR in the upcoming period, according to Goldman is $4 based on the research report published on December 18, 2024 of the previous year 2024.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see ESPR reach a price target of $8. The rating they have provided for ESPR stocks is “Overweight” according to the report published on December 17th, 2024.
BofA Securities gave a rating of “Underperform” to ESPR, setting the target price at $2.50 in the report published on June 20th of the previous year.
ESPR Trading at -5.25% from the 50-Day Moving Average
After a stumble in the market that brought ESPR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.84% of loss for the given period.
Volatility was left at 7.40%, however, over the last 30 days, the volatility rate increased by 6.83%, as shares sank -4.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.82% lower at present.
During the last 5 trading sessions, ESPR rose by +12.99%, which changed the moving average for the period of 200-days by -22.67% in comparison to the 20-day moving average, which settled at $1.6255. In addition, Esperion Therapeutics Inc saw -20.91% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ESPR starting from Halladay Benjamin, who sale 3,535 shares at the price of $1.48 back on Mar 18 ’25. After this action, Halladay Benjamin now owns 481,710 shares of Esperion Therapeutics Inc, valued at $5,242 using the latest closing price.
Warren Eric, the Chief Commercial Officer of Esperion Therapeutics Inc, sale 2,433 shares at $1.49 during a trade that took place back on Mar 18 ’25, which means that Warren Eric is holding 370,326 shares at $3,618 based on the most recent closing price.
Stock Fundamentals for ESPR
Current profitability levels for the company are sitting at:
- 0.16 for the present operating margin
- 0.79 for the gross margin
The net margin for Esperion Therapeutics Inc stands at -0.16. The total capital return value is set at 0.56.
Based on Esperion Therapeutics Inc (ESPR), the company’s capital structure generated -3.27 points at debt to capital in total, while cash flow to debt ratio is standing at -0.08. The debt to equity ratio resting at -0.77. The interest coverage ratio of the stock is 0.92.
Currently, EBITDA for the company is 7.57 million with net debt to EBITDA at 20.19. When we switch over and look at the enterprise to sales, we see a ratio of 1.5. The receivables turnover for the company is 4.15for trailing twelve months and the total asset turnover is 0.97. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.37.
Conclusion
In a nutshell, Esperion Therapeutics Inc (ESPR) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
